Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series
Gespeichert in:
| Veröffentlicht in: | Respiratory investigation 2020-11, Vol.58 (6), p.510-512 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 512 |
|---|---|
| container_issue | 6 |
| container_start_page | 510 |
| container_title | Respiratory investigation |
| container_volume | 58 |
| creator | Nakamura, Hideta Miyagi, Kazuya Otsuki, Mariko Higure, Yuuri Nishiyama, Naoya Kinjo, Takeshi Nakamatsu, Masashi Haranaga, Shusaku Tateyama, Masao Fujita, Jiro |
| description | |
| doi_str_mv | 10.1016/j.resinv.2020.09.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539801</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2212534520301337</els_id><sourcerecordid>2451848475</sourcerecordid><originalsourceid>FETCH-LOGICAL-c436t-492c1e422f73e5def3445ffbdfae944f7d7b5514b35386b5fb2fd6fc4107b94e3</originalsourceid><addsrcrecordid>eNp9Uctu1DAUtRCIVkP_ACEv2STYjp1MWCBVUx5FlbqhbC3HvmY8JHGwnUHhq_qJ9WjKABu8se_jnOt7DkIvKSkpofWbXRkgunFfMsJISdqSkPoJOmeMskJUonp6enNxhi5i3JF8asE4rZ-js6oidUN5e47u7yJgb3HaAnZjgtDD_N2NuM7R1nUu-YCT1653v-ZBdTmLP6tJjZBhk0oOxhTxT5e2WC_JZyTgAD2oXI7LaIIfAGs1RzC4W_Dm9uv1VUHbIveolHNKz-mAiJMLKs9asHEx5Tie4G_xZWY48EFwEF-gZ1b1ES4e7xW6-_D-y-ZTcXP78XpzeVNoXtWp4C3TFDhjtqlAGLAV58LazlgFLee2MU0nBOVdFmtdd8J2zJraak5J07UcqhV6d-Sd5m4Ao_OiQfVyCm5QYZFeOflvZXRb-c3vZSOqdk1oJnj9SBD8jxlikoOLGvo-i-fnKBkXdM3XPPevED-26uBjDGBPYyiRB7_lTh79lge_JWllNjPDXv39xRPot7t_doAs1N5BkFFnxzQYF0Anabz7_4QHX-zDaw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451848475</pqid></control><display><type>article</type><title>Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro</creator><creatorcontrib>Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro</creatorcontrib><identifier>ISSN: 2212-5345</identifier><identifier>EISSN: 2212-5353</identifier><identifier>DOI: 10.1016/j.resinv.2020.09.006</identifier><identifier>PMID: 33067149</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; COVID-19 - drug therapy ; Cytokine Release Syndrome - drug therapy ; Cytokine Release Syndrome - virology ; Humans ; Interleukin-6 - antagonists & inhibitors ; Japan - epidemiology ; Letter to the Editor ; Respiratory Distress Syndrome - drug therapy ; Respiratory Distress Syndrome - virology</subject><ispartof>Respiratory investigation, 2020-11, Vol.58 (6), p.510-512</ispartof><rights>2020 The Japanese Respiratory Society</rights><rights>2020 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved. 2020 The Japanese Respiratory Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c436t-492c1e422f73e5def3445ffbdfae944f7d7b5514b35386b5fb2fd6fc4107b94e3</cites><orcidid>0000-0001-7686-4604</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33067149$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nakamura, Hideta</creatorcontrib><creatorcontrib>Miyagi, Kazuya</creatorcontrib><creatorcontrib>Otsuki, Mariko</creatorcontrib><creatorcontrib>Higure, Yuuri</creatorcontrib><creatorcontrib>Nishiyama, Naoya</creatorcontrib><creatorcontrib>Kinjo, Takeshi</creatorcontrib><creatorcontrib>Nakamatsu, Masashi</creatorcontrib><creatorcontrib>Haranaga, Shusaku</creatorcontrib><creatorcontrib>Tateyama, Masao</creatorcontrib><creatorcontrib>Fujita, Jiro</creatorcontrib><title>Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series</title><title>Respiratory investigation</title><addtitle>Respir Investig</addtitle><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>COVID-19 - drug therapy</subject><subject>Cytokine Release Syndrome - drug therapy</subject><subject>Cytokine Release Syndrome - virology</subject><subject>Humans</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Japan - epidemiology</subject><subject>Letter to the Editor</subject><subject>Respiratory Distress Syndrome - drug therapy</subject><subject>Respiratory Distress Syndrome - virology</subject><issn>2212-5345</issn><issn>2212-5353</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9Uctu1DAUtRCIVkP_ACEv2STYjp1MWCBVUx5FlbqhbC3HvmY8JHGwnUHhq_qJ9WjKABu8se_jnOt7DkIvKSkpofWbXRkgunFfMsJISdqSkPoJOmeMskJUonp6enNxhi5i3JF8asE4rZ-js6oidUN5e47u7yJgb3HaAnZjgtDD_N2NuM7R1nUu-YCT1653v-ZBdTmLP6tJjZBhk0oOxhTxT5e2WC_JZyTgAD2oXI7LaIIfAGs1RzC4W_Dm9uv1VUHbIveolHNKz-mAiJMLKs9asHEx5Tie4G_xZWY48EFwEF-gZ1b1ES4e7xW6-_D-y-ZTcXP78XpzeVNoXtWp4C3TFDhjtqlAGLAV58LazlgFLee2MU0nBOVdFmtdd8J2zJraak5J07UcqhV6d-Sd5m4Ao_OiQfVyCm5QYZFeOflvZXRb-c3vZSOqdk1oJnj9SBD8jxlikoOLGvo-i-fnKBkXdM3XPPevED-26uBjDGBPYyiRB7_lTh79lge_JWllNjPDXv39xRPot7t_doAs1N5BkFFnxzQYF0Anabz7_4QHX-zDaw</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Nakamura, Hideta</creator><creator>Miyagi, Kazuya</creator><creator>Otsuki, Mariko</creator><creator>Higure, Yuuri</creator><creator>Nishiyama, Naoya</creator><creator>Kinjo, Takeshi</creator><creator>Nakamatsu, Masashi</creator><creator>Haranaga, Shusaku</creator><creator>Tateyama, Masao</creator><creator>Fujita, Jiro</creator><general>Elsevier B.V</general><general>The Japanese Respiratory Society. Published by Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7686-4604</orcidid></search><sort><creationdate>20201101</creationdate><title>Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series</title><author>Nakamura, Hideta ; Miyagi, Kazuya ; Otsuki, Mariko ; Higure, Yuuri ; Nishiyama, Naoya ; Kinjo, Takeshi ; Nakamatsu, Masashi ; Haranaga, Shusaku ; Tateyama, Masao ; Fujita, Jiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c436t-492c1e422f73e5def3445ffbdfae944f7d7b5514b35386b5fb2fd6fc4107b94e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>COVID-19 - drug therapy</topic><topic>Cytokine Release Syndrome - drug therapy</topic><topic>Cytokine Release Syndrome - virology</topic><topic>Humans</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Japan - epidemiology</topic><topic>Letter to the Editor</topic><topic>Respiratory Distress Syndrome - drug therapy</topic><topic>Respiratory Distress Syndrome - virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nakamura, Hideta</creatorcontrib><creatorcontrib>Miyagi, Kazuya</creatorcontrib><creatorcontrib>Otsuki, Mariko</creatorcontrib><creatorcontrib>Higure, Yuuri</creatorcontrib><creatorcontrib>Nishiyama, Naoya</creatorcontrib><creatorcontrib>Kinjo, Takeshi</creatorcontrib><creatorcontrib>Nakamatsu, Masashi</creatorcontrib><creatorcontrib>Haranaga, Shusaku</creatorcontrib><creatorcontrib>Tateyama, Masao</creatorcontrib><creatorcontrib>Fujita, Jiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Respiratory investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nakamura, Hideta</au><au>Miyagi, Kazuya</au><au>Otsuki, Mariko</au><au>Higure, Yuuri</au><au>Nishiyama, Naoya</au><au>Kinjo, Takeshi</au><au>Nakamatsu, Masashi</au><au>Haranaga, Shusaku</au><au>Tateyama, Masao</au><au>Fujita, Jiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series</atitle><jtitle>Respiratory investigation</jtitle><addtitle>Respir Investig</addtitle><date>2020-11-01</date><risdate>2020</risdate><volume>58</volume><issue>6</issue><spage>510</spage><epage>512</epage><pages>510-512</pages><issn>2212-5345</issn><eissn>2212-5353</eissn><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33067149</pmid><doi>10.1016/j.resinv.2020.09.006</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7686-4604</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2212-5345 |
| ispartof | Respiratory investigation, 2020-11, Vol.58 (6), p.510-512 |
| issn | 2212-5345 2212-5353 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7539801 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use COVID-19 - drug therapy Cytokine Release Syndrome - drug therapy Cytokine Release Syndrome - virology Humans Interleukin-6 - antagonists & inhibitors Japan - epidemiology Letter to the Editor Respiratory Distress Syndrome - drug therapy Respiratory Distress Syndrome - virology |
| title | Use of the interleukin 6 inhibitor tocilizumab in Japanese patients with cytokine release syndrome caused by COVID-19-related acute respiratory distress syndrome: A case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A24%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20the%20interleukin%206%20inhibitor%20tocilizumab%20in%20Japanese%20patients%20with%20cytokine%20release%20syndrome%20caused%20by%20COVID-19-related%20acute%20respiratory%20distress%20syndrome:%20A%20case%20series&rft.jtitle=Respiratory%20investigation&rft.au=Nakamura,%20Hideta&rft.date=2020-11-01&rft.volume=58&rft.issue=6&rft.spage=510&rft.epage=512&rft.pages=510-512&rft.issn=2212-5345&rft.eissn=2212-5353&rft_id=info:doi/10.1016/j.resinv.2020.09.006&rft_dat=%3Cproquest_pubme%3E2451848475%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451848475&rft_id=info:pmid/33067149&rft_els_id=S2212534520301337&rfr_iscdi=true |